These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 15628907)

  • 21. Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.
    Fountzilas G; Christodoulou C; Bobos M; Kotoula V; Eleftheraki AG; Xanthakis I; Batistatou A; Pentheroudakis G; Xiros N; Papaspirou I; Koumarianou A; Papakostas P; Bafaloukos D; Skarlos DV; Kalogeras KT
    J Transl Med; 2012 Oct; 10():212. PubMed ID: 23092535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.
    Mueller RE; Parkes RK; Andrulis I; O'Malley FP
    Genes Chromosomes Cancer; 2004 Apr; 39(4):288-97. PubMed ID: 14978790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aberrations of ERBB2 and TOP2A genes in breast cancer.
    Nielsen KV; Müller S; Møller S; Schønau A; Balslev E; Knoop AS; Ejlertsen B
    Mol Oncol; 2010 Apr; 4(2):161-8. PubMed ID: 19945923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
    Hicks DG; Yoder BJ; Pettay J; Swain E; Tarr S; Hartke M; Skacel M; Crowe JP; Budd GT; Tubbs RR
    Hum Pathol; 2005 Apr; 36(4):348-56. PubMed ID: 15891995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas].
    Liang ZY; Wang WZ; Gao J; Wu SF; Zeng X; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):102-6. PubMed ID: 17493384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TOP2A amplification in the absence of that of HER-2/neu: toward individualization of chemotherapeutic practice in breast cancer.
    Glynn RW; Mahon S; Curran C; Callagy G; Miller N; Kerin MJ
    Oncologist; 2011; 16(7):949-55. PubMed ID: 21705665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer.
    Järvinen TA; Liu ET
    Curr Cancer Drug Targets; 2006 Nov; 6(7):579-602. PubMed ID: 17100565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
    Menendez JA; Vellon L; Lupu R
    Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene copy mapping of the ERBB2/TOP2A region in breast cancer.
    Jacobson KK; Morrison LE; Henderson BT; Blondin BA; Wilber KA; Legator MS; O'Hare A; Van Stedum SC; Proffitt JH; Seelig SA; Coon JS
    Genes Chromosomes Cancer; 2004 May; 40(1):19-31. PubMed ID: 15034864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.
    Järvinen TA; Tanner M; Rantanen V; Bärlund M; Borg A; Grénman S; Isola J
    Am J Pathol; 2000 Mar; 156(3):839-47. PubMed ID: 10702400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
    Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.
    Arriola E; Marchio C; Tan DS; Drury SC; Lambros MB; Natrajan R; Rodriguez-Pinilla SM; Mackay A; Tamber N; Fenwick K; Jones C; Dowsett M; Ashworth A; Reis-Filho JS
    Lab Invest; 2008 May; 88(5):491-503. PubMed ID: 18332872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations.
    Hagen AI; Bofin AM; Ytterhus B; Maehle LO; Kjellevold KH; Myhre HO; Møller P; Lønning PE
    Acta Oncol; 2007; 46(2):199-203. PubMed ID: 17453369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.
    Villman K; Sjöström J; Heikkilä R; Hultborn R; Malmström P; Bengtsson NO; Söderberg M; Saksela E; Blomqvist C
    Acta Oncol; 2006; 45(5):590-6. PubMed ID: 16864174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes.
    Olsen KE; Knudsen H; Rasmussen BB; Balslev E; Knoop A; Ejlertsen B; Nielsen KV; Schönau A; Overgaard J;
    Acta Oncol; 2004; 43(1):35-42. PubMed ID: 15068318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction.
    Lehmann U; Glöckner S; Kleeberger W; von Wasielewski HF; Kreipe H
    Am J Pathol; 2000 Jun; 156(6):1855-64. PubMed ID: 10854209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Classical lobular breast carcinoma consistently lacks topoisomerase-IIα gene amplification: implications for the tailored use of anthracycline-based chemotherapies.
    Brunello E; Brunelli M; Manfrin E; Nottegar A; Bersani S; Vergine M; Molino A; Fiorio E; Chilosi M; Gobbo S; Martignoni G; Bonetti F
    Histopathology; 2012 Feb; 60(3):482-8. PubMed ID: 22168383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Tibau A; López-Vilaró L; Pérez-Olabarria M; Vázquez T; Pons C; Gich I; Alonso C; Ojeda B; Ramón y Cajal T; Lerma E; Barnadas A; Escuin D
    Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.
    Sønderstrup IM; Nygård SB; Poulsen TS; Linnemann D; Stenvang J; Nielsen HJ; Bartek J; Brünner N; Nørgaard P; Riis L
    Mol Oncol; 2015 Jun; 9(6):1207-17. PubMed ID: 25777966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.